Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 352

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Open access
Palumbo, Antonio, Bringhen, Sara, Ludwig, Heinz, Dimopoulos, Meletios A., Bladé, Joan, Mateos, Maria V., Rosiñol, Laura, Boccadoro, Mario, Cavo, Michele, Lokhorst, Henk, Zweegman, Sonja, Terpos, Evangelos, Davies, Faith, Driessen, Christoph, Gimsing, Peter, Gramatzki, Martin, Hàjek, Roman, Johnsen, Hans E., Leal Da Costa, Fernando, Sezer, Orhan, Spencer, Andrew, Beksac, Meral, Morgan, Gareth, Einsele, Hermann, San Miguel, Jesus F., Sonneveld, Pieter·2011·Blood

Abstract

Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with MM are ineligible for autologous transplantation, and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has improved outcomes; however, elderly patients with MM are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate screening for vulnerability and an assessment of cardiac, pulmonary, renal, hepatic, and neurologic functions, as well as age > 75 years, at the start of therapy allows treatment strategies to be individualized and drug doses to be tailored to improve tolerability and optimize efficacy. Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-06-358812

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 352

Metadata

Authors
Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H., Zweegman, S., Terpos, E., Davies, F., Driessen, C., Gimsing, P., Gramatzki, M., Hàjek, R., Johnsen, H. E., Leal Da Costa, F., Sezer, O., Spencer, A., Beksac, M., Morgan, G., Einsele, H., San Miguel, J. F., & Sonneveld, P.
Venue
Blood
Published
2011-10-27
Volume
118
Issue
17
Pages
4519-4529
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2056804811
Cited by
352
References
10
FWCI
17.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). https://app.cochat.ai/papers/10.1182/blood-2011-06-358812
The paper
Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H., Zweegman, S., Terpos, E., Davies, F., Driessen, C., Gimsing, P., Gramatzki, M., Hàjek, R., Johnsen, H. E., Leal Da Costa, F., . . . Sonneveld, P. (2011). Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. https://doi.org/10.1182/blood-2011-06-358812

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.